Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Updated findings from the phase 3 NATALEE trial (NCT03701334) demonstrated that 3-year treatment with ribociclib (Kisqali) in combination with a nonsteroidal aromatase inhibitor (NSAI) remained well tolerated, and dose reductions did not appear to affect …